Skip to main content

Ethiodized Oil Shortage

Last Updated: September 17, 2019
Status: Resolved

Reason for the Shortage
    • Guerbet has Lipiodol injection available.[1]
    • Guerbet has transferred the manufacturing of Lipiodol injection to the US. As of March 2019, Lipiodol Ultra-Fluide is no longer being imported.[1]
    • Guerbet had Lipiodol injection in short supply due to manufacturing problems at Jubilant HollisterStier, the manufacturing site in Canada that supplies Lipiodol for Guerbet.[1-2]
Available Products
    • Lipiodol injection, Guerbet, 10 mL vial, NDC 67684-1901-02

Implications for Patient Care

    • Ethiodized oil is a lipophilic non-ionic iodinated contrast medium, derived from poppy seed oil.[3] Lipiodol is the only lipophilic non-ionic contrast media approved in the US.[3-4]
    • Ethiodized oil is labeled for use in patients undergoing hysterosalpingography or lymphography and for hepatic intra-arterial use for imaging tumors in patients with hepatocellular carcinoma.[3]
    • Ethiodized oil is also commonly used in chemoembolization procedures for the treatment of primary and secondary hepatic malignancies.[5-7]


    1. Guerbet. Personal communication. June 3, July 13, December 16, 2015; February 17, April 26, June 28, September 20, December 12, 2016; March 13, June 20, October 5 and 10, 2017; January 17, April 11, July 17, October 25, 2018; February 7, May 15, July 17, and September 17, 2019.
    2. Guerbet. Dear Healthcare Professional Letter. June 1, 2015. Available online at Accessed June 2, 2015.
    3. Lipiodol (ethiodized oil) injection product information. Bloomington, IN: Guerbet, April 2014.
    4. Swanson D, Maywood C. Miscellaneous radiopaque contrast media. II. Hysterosalpingographic contrast media. In: Swanson D, Chilton H, Thrall J, eds. Pharmaceuticals in Medical Imaging. Radiopaque Contrast Media, Radiopharmaceuticals, Enhancement Agents for Magnetic Resonance Imaging and Ultrasound. New York, NY: MacMillan Publishing Co; 1990:227-236.
    5. American College of Radiology. ACR Appropriateness Criteria. Radiologic Management of Hepatic Malignancy, 2011: Accessed June 2, 2015.
    6. Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs. Jun 2004;15(5):427-437.
    7. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. Feb 2006;17(2 Pt 1):217-223.


Updated September 17, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 3, 2015 by Erin R. Fox, PharmD, Director, Drug Information Service. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.